YIH
NYMX

Y-Intercept (HK)’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Y-Intercept (HK)’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,391
Closed -$16K – 986
2021
Q2 		$16K Buy
+10,391
New +$19.3K ﹤0.01% 587

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Y-Intercept (HK)'s NYMX Position: Q3 2021 in Review

Y-Intercept (HK) sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2021, closing a stake of 10,391 shares — an estimated $16K sold.

Y-Intercept (HK) first reported a position in NYMX in Q2 2021 and held it in 1 quarter. The position peaked at $16K in Q2 2021. 38 funds tracked by Wall St. Rank hold NYMX as of Q3 2021.

  • Y-Intercept (HK) reported no remaining Nymox Pharmaceutical Corp position as of Q3 2021 after selling out during the quarter.
  • Y-Intercept (HK) sold 10,391 Nymox Pharmaceutical Corp shares in Q3 2021, an estimated $16K.
  • Y-Intercept (HK) first reported a position in Nymox Pharmaceutical Corp in Q2 2021 and held it in 1 quarter.
  • Y-Intercept (HK)'s Nymox Pharmaceutical Corp position peaked at $16K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2021.

Based on Y-Intercept (HK)'s 13F filing for Q3 2021, filed 15 Nov 2021.